** Shares of Pittsburgh-based drug developer Lipella Pharmaceuticals LIPO.O rise 68.20% to $5.14 premarket
** LIPO says its experimental drug, LP-310, showed a strong safety profile in a small study of 24 patients with oral lichen planus $(OLP)$, a chronic inflammatory disease that affects mucous membranes inside the mouth
** Co says no drug-related serious adverse events were found in study, and no patients dropped out
** LIPO says LP-310, an oral rinse topical treatment, helped meaningfully reduce pain, ulceration, and inflammation for patients in the study
** Co plans to submit marketing application for LP-310 to the FDA in H2 2025
** In the last 12 months, the stock has fallen 63.34%
(Reporting by Siddhi Mahatole)
((siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.